What Tyra Biosciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 1 |
| Sells | 0 | 14 |
| Total trades | 4 | 28 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 5,712 | 170,192 |
| Disposed | 0 | 658,510 |
| Net activity | +5,712 | −488,318 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Rueb Yuliya | Vice President, Finance (PAO) | Sep 15 | Grant / award · A | +2,925 | $9.13 | +$26.7K | 11,258 |
| Harris Todd | President and CEO | Sep 15 | Grant / award · A | +864 | $9.13 | +$7.89K | 1,438,495 |
| Fuhrman Alan | Chief Financial Officer | Sep 15 | Grant / award · A | +951 | $9.13 | +$8.68K | 37,115 |
| Verjee Rehan | Director | Sep 09 | Open-market buy · P | +972 | $20.58 | +$20K | 972 |
| Rueb Yuliya | Vice President, Finance (PAO) | May 05 | Grant / award · A | +8,333 | — | — | 43,354 |
| Ashar Bhavesh | Chief Operating Officer | May 05 | Grant / award · A | +15,013 | — | — | 15,013 |
| Harris Todd | President and CEO | May 05 | Grant / award · A | +79,000 | — | — | 1,437,631 |
| Fuhrman Alan | Chief Financial Officer | May 05 | Grant / award · A | +20,000 | — | — | 36,164 |
| Warner Douglas J | Chief Medical Officer | May 05 | Grant / award · A | +25,000 | — | — | 25,000 |
| Kaplan Gilla Phd | Director | Mar 26 | Disposition to Issuer · D | −53,172 | $37.75 | −$2.01M | 28,231 |
| Kaplan Gilla Phd | Director | Mar 26 | Exercise / conversion · M | −53,172 | $2.25 | −$120K | 81,403 |
| Kaplan Gilla Phd | Director | Mar 25 | Open-market sale · S | −14,295 | $36.97 | −$529K | 28,231 |
| Kaplan Gilla Phd | Director | Mar 25 | Exercise / conversion · M | +14,295 | $2.25 | +$32.2K | 42,526 |
| Harris Todd | President and CEO | Mar 13 | Grant / award · A | +1,463 | $9.13 | +$13.4K | 1,358,631 |
| Fuhrman Alan | Chief Financial Officer | Mar 13 | Grant / award · A | +1,376 | $9.13 | +$12.6K | 16,164 |
| Bensen Daniel | Chief Discovery Officer | Feb 12 | Open-market sale · S | −5,872 | $33.37 | −$196K | 146,981 |
| Bensen Daniel | Chief Discovery Officer | Feb 12 | Open-market sale · S | −2,128 | $31.50 | −$67K | 152,853 |
| Bensen Daniel | Chief Discovery Officer | Jan 12 | Open-market sale · S | −1,017 | $29.08 | −$29.6K | 154,981 |
| Bensen Daniel | Chief Discovery Officer | Jan 12 | Open-market sale · S | −6,983 | $28.44 | −$199K | 155,998 |
| More Robert J | Director | Dec 19 | Open-market sale · S | −10,000 | $25.00 | −$250K | 3,823,425 |
Loading...
